Transgender hormone therapy: understanding international variation in practice

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 4, 2017, Pages 243-246

  Mamoojee, Yaasir ^a   Seal, Leighton J ^b,c,d   Quinton, Richard ^a,e  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CYPROTERONE; ESTRADIOL; ETHINYLESTRADIOL; GONADORELIN DERIVATIVE; PROGESTERONE DERIVATIVE; SPIRONOLACTONE; TESTOSTERONE;

ACNE; BONE DISEASE; BREAST AUGMENTATION; BREAST CANCER; BREAST HYPOPLASIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG COST; ERYTHROCYTOSIS; GENDER DYSPHORIA; HAIR REMOVAL; HEALTH CARE COST; HEALTH INSURANCE; HIGH INCOME COUNTRY; HORMONAL THERAPY; HUMAN; HYPERKALEMIA; HYPOGONADISM; IRAN; KIDNEY DYSFUNCTION; LIFESTYLE; LIVER DYSFUNCTION; LOW INCOME COUNTRY; MENINGIOMA; MOOD DISORDER; MOTIVATION; NETHERLANDS; NOTE; OBESITY; PATIENT ATTITUDE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK ASSESSMENT; SIDE EFFECT; SMOKING; SOCIAL CLASS; THAILAND; THROMBOSIS; TRANSDERMAL PATCH; TRANSGENDER; TRANSGENDERISM; UNITED KINGDOM; UNITED STATES; URBAN AREA; UROLOGIC SURGERY; VAGINA RECONSTRUCTION; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; FEMALE; HORMONE SUBSTITUTION; MALE; SEX REASSIGNMENT; TRANSSEXUALISM;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; SEX REASSIGNMENT PROCEDURES; TRANSGENDER PERSONS; TRANSSEXUALISM;

EID: 85015899628     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30068-2     Document Type: Note

References (15)

1. 1 Coleman, E, Bockting, W, Botzer, M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend 13 (2011), 165–232.
2. 2 Wylie, K, Barrett, J, Besser, GM, et al. Good practice guidelines for the assessment and treatment of adults with gender dysphoria. Sex Relation Ther 2 (2014), 154–214.
3. 3 Saberi, SM, Mirsepassi, GR, Forensic psychiatry in Iran. Iran J Psychiatry Behav Sci 7 (2013), 1–3.
4. 4 HM Home Office. Country information and guidance—Iran: sexual orientation and gender identity. Version 2.0. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/565824/CIG-Iran-SOGI-v2-September-2016.pdf, September, 2016 (accessed Feb 28, 2017).
5. 5 Seal, LJ, Franklin, S, Richards, C, et al. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab 97 (2012), 4422–4428.
6. 6 Seal, LJ, A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria. Ann Clin Biochem 53 (2016), 10–20.
7. 7 Meyer, WJ, Webb, A, Stuart, CA, et al. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Arch Sex Behav 15 (1986), 121–138.
8. 8 Hembree, WC, Cohen-Kettenis, P, Delemarre-van de Waal, HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94 (2009), 3132–3154.
9. 9 Van Kesteren, PJ, Asscheman, H, Megens, JA, et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47 (1997), 337–342.
10. 10 Bergendal, A, Kieler, H, Sundström, A, Hirschberg, AL, Kocoska-Maras, L, Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 23 (2016), 593–599.
11. 11 Wierckx, K, Gooren, L, T'sjoen, G, Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med 11 (2014), 1240–1247.
12. 12 Gooren, L, Hormone treatment of the adult transsexual patient. Horm Res 64:suppl 2 (2005), 31–36.
13. 13 Rossouw, JE, Anderson, GL, Prentice, RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002), 321–333.
14. 14 Hulley, S, Grady, D, Bush, T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998), 605–613.
15. 15 Dittrich, R, Binder, H, Cupisti, S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 113 (2005), 586–592.